|
1.
|
Rapidis AD, Givalos N, Gakiopoulou H, et
al: Adenoid cystic carcinoma of the head and neck.
Clinicopathological analysis of 23 patients and review of the
literature. Oral Oncol. 41:328–335. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Ampil FL and Misra RP: Factors influencing
survival of patients with adenoid cystic carcinoma of the salivary
glands. J Oral Maxillofac Surg. 45:1005–1010. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Ishii K, Shimoda M, Sugiura T, et al:
Involvement of epithelial-mesenchymal transition in adenoid cystic
carcinoma metastasis. Int J Oncol. 38:921–931. 2011.PubMed/NCBI
|
|
4.
|
Shimoda M, Sugiura T, Imajyo I, et al: The
T-box transcription factor Brachyury regulates
epithelial-mesenchymal transitions in association with cancer
stem-like cells in adenoid cystic carcinoma cells. BMC Cancer.
12:3772012. View Article : Google Scholar
|
|
5.
|
Grunert S, Jechlinger M and Beug H:
Diverse cellular and molecular mechanisms contribute to epithelial
plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Cano A, Perez-Moreno MA, Rodrigo I, et al:
The transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Yang MH, Hsu DS, Wang HW, et al: Bmil is
essential in Twistl-induced epithelial-mesenchymal transition. Nat
Cell Biol. 12:982–992. 2010. View
Article : Google Scholar
|
|
8.
|
Kispert A, Herrmann BG, Leptin M and
Reuter R: Homologs of the mouse Brachyury gene are involved in the
specification of posterior terminal structures in Drosophila,
Tribolium, and Locusta. Genes Dev. 8:2137–2150. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Behr R, Heneweer C, Viebahn C, Denker HW
and Thie M: Epithelial-mesenchymal transition in colonies of rhesus
monkey embryonic stem cells: a model for processes involved in
gastrulation. Stem Cells. 23:805–816. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Vidricaire G, Jardine K and McBurney MW:
Expression of the Brachyury gene during mesoderm development in
differentiating embryonal carcinoma cell cultures. Development.
120:115–122. 1994.PubMed/NCBI
|
|
11.
|
Fernando RI, Litzinger M, Trono P,
Hamilton DH, Schlom J and Palena C: The T-box transcription factor
Brachyury promotes epithelial-mesenchymal transition in human tumor
cells. J Clin Invest. 120:533–544. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Thiery JP: Epithelial-mesenchymal
transitions in development and pathologies. Curr Opin Cell Biol.
15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Mani SA, Guo W, Liao MJ, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Blick T, Hugo H, Widodo E, et al:
Epithelial mesenchymal transition traits in human breast cancer
cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in
human breast cancer. J Mammary Gland Biol Neoplasia. 15:235–252.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Huang HP, Chen PH, Yu CY, et al:
Epithelial cell adhesion molecule (EpCAM) complex proteins promote
transcription factor-mediated pluripotency reprogramming. J Biol
Chem. 286:33520–33532. 2011. View Article : Google Scholar
|
|
17.
|
Utikal J, Maherali N, Kulalert W and
Hochedlinger K: Sox2 is dispensable for the reprogramming of
melanocytes and melanoma cells into induced pluripotent stem cells.
J Cell Sci. 122:3502–3510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Ahmed N, Abubaker K, Findlay J and Quinn
M: Epithelial mesenchymal transition and cancer stem cell-like
phenotypes facilitate chemoresistance in recurrent ovarian cancer.
Curr Cancer Drug Targets. 10:268–278. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Alison MR, Lim SM and Nicholson LJ: Cancer
stem cells: problems for therapy? J Pathol. 223:147–161.
2010.PubMed/NCBI
|
|
20.
|
Wang Z, Li Y, Ahmad A, Azmi AS, Kong D,
Banerjee S and Sarkar FH: Targeting miRNAs involved in cancer stem
cell and EMT regulation: an emerging concept in overcoming drug
resistance. Drug Resist Updat. 13:109–118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Raimondi C, Gianni W, Cortesi E and
Gazzaniga P: Cancer stem cells and epithelial-mesenchymal
transition: revisiting minimal residual disease. Curr Cancer Drug
Targets. 10:496–508. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Herrmann BG, Labeit S, Poustka A, King TR
and Lehrach H: Cloning of the T gene required in mesoderm formation
in the mouse. Nature. 343:617–622. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Edwards YH, Putt W, Lekoape KM, Stott D,
Fox M, Hopkinson DA and Sowden J: The human homolog T of the mouse
T(Brachyury) gene; gene structure, cDNA sequence, and assignment to
chromosome 6q27. Genome Res. 6:226–233. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Sarkar D, Shields B, Davies ML, Muller J
and Wakeman JA: BRACHYURY confers cancer stem cell characteristics
on colorectal cancer cells. Int J Cancer. 130:328–337. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Abe M, Sugiura T, Takahashi M, Ishii K,
Shimoda M and Shirasuna K: A novel function of CD82/KAI-1 on
E-cadherin-mediated homophilic cellular adhesion of cancer cells.
Cancer Lett. 266:163–170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Brown AM: A step-by-step guide to
non-linear regression analysis of experimental data using a
Microsoft Excel spreadsheet. Comput Methods Programs Biomed.
65:191–200. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Hsu HS, Huang PI and Chang YL: et al
Cucurbitacin I inhibits tumorigenic ability and enhances
radiochemosensitivity in nonsmall cell lung cancer-derived
CD133-positive cells. Cancer. 117:2970–2985. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Cheung ST, Cheung PF, Cheng CK, Wong NC
and Fan ST: Granulin-epithelin precursor and ATP-dependent binding
cassette (ABC)B5 regulate liver cancer cell chemoresistance.
Gastroenterology. 140:344–355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Chuthapisith S, Eremin J, El-Sheemey M and
Eremin O: Breast cancer chemoresistance: emerging importance of
cancer stem cells. Surg Oncol. 19:27–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Hayashi Y, Osanai M and Lee GH: Fascin-1
expression correlates with repression of E-cadherin expression in
hepatocellular carcinoma cells and augments their invasiveness in
combination with matrix metalloproteinases. Cancer Sci.
102:1228–1235. 2011. View Article : Google Scholar
|
|
31.
|
Lin CY, Tsai PH, Kandaswami CC, Lee PP,
Huang CJ, Hwang JJ and Lee MT: Matrix metalloproteinase-9
cooperates with transcription factor Snail to induce
epithelial-mesenchymal transition. Cancer Sci. 102:815–827. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Zhang K, Chen D, Jiao X, et al: Slug
enhances invasion ability of pancreatic cancer cells through
upregulation of matrix metalloproteinase-9 and actin cytoskeleton
remodeling. Lab Invest. 91:426–438. 2011. View Article : Google Scholar
|
|
33.
|
Zuo JH, Zhu W, Li MY, et al: Activation of
EGFR promotes squamous carcinoma SCC10A cell migration and invasion
via inducing EMT-like phenotype change and MMP-9-mediated
degradation of E-cadherin. J Cell Biochem. 112:2508–2517. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Huang Y and Sadee W: Membrane transporters
and channels in chemoresistance and -sensitivity of tumor cells.
Cancer Lett. 239:168–182. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Huang Y: Pharmacogenetics/genomics of
membrane transporters in cancer chemotherapy. Cancer Metastasis
Rev. 26:183–201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S,
Kim S and Kim H: ID4 imparts chemoresistance and cancer sternness
to glioma cells by derepressing miR-9*-mediated suppression of
SOX2. Cancer Res. 71:3410–3421. 2011.PubMed/NCBI
|
|
37.
|
Yang R, Li WW, Hoang BH, et al:
Quantitative correlation between promoter methylation and messenger
RNA levels of the reduced folate carrier. BMC Cancer. 8:1242008.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Matherly LH, Hou Z and Deng Y: Human
reduced folate carrier: translation of basic biology to cancer
etiology and therapy. Cancer Metastasis Rev. 26:111–128.
2007.PubMed/NCBI
|
|
39.
|
Harper LJ, Costea DE, Gammon L, Fazil B,
Biddle A and Mackenzie IC: Normal and malignant epithelial cells
with stem-like properties have an extended G2 cell cycle phase that
is associated with apoptotic resistance. BMC Cancer.
10:1662010.PubMed/NCBI
|
|
40.
|
Dorr RT: Bleomycin pharmacology: mechanism
of action and resistance, and clinical pharmacokinetics. Semin
Oncol. 19:3–8. 1992.PubMed/NCBI
|
|
41.
|
Song B, Wang Y, Xi Y, et al: Mechanism of
chemoresistance mediated by miR-140 in human osteosarcoma and colon
cancer cells. Oncogene. 28:4065–4074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Lin CK, Nguyen TT, Morgan TL, et al:
Apoptosis may be either suppressed or enhanced with strategic
combinations of antineoplastic drugs or anti-IgM. Exp Cell Res.
244:1–13. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
O’Leary J, Volm M, Wasserheit C and Muggia
F: Taxanes in adjuvant and neoadjuvant therapies for breast cancer.
Oncology (Williston Park). 12:23–27. 1998.
|
|
44.
|
Hittelman WN, Liao Y, Wang L and Milas L:
Are cancer stem cells radioresistant? Future Oncol. 6:1563–1576.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Pajonk F, Vlashi E and McBride WH:
Radiation resistance of cancer stem cells: the 4 R’s of
radiobiology revisited. Stem Cells. 28:639–648. 2010.
|
|
46.
|
Al-Assar O, Mantoni T, Lunardi S, Kingham
G, Helleday T and Brunner TB: Breast cancer stem-like cells show
dominant homologous recombination due to a larger S-G2 fraction.
Cancer BiolTher. 11:1028–1035. 2011.PubMed/NCBI
|
